Shanghai Hile Bio-Technology Co., Ltd. (SHA:603718)
China
· Delayed Price · Currency is CNY 4.900
+0.060 (1.24%)
Mar 10, 2026, 3:00 PM CST
SHA:603718 Revenue
Shanghai Hile Bio-Technology had revenue of 39.97M CNY in the quarter ending September 30, 2025, a decrease of -40.20%. This brings the company's revenue in the last twelve months to 246.35M, up 11.70% year-over-year. In the year 2024, Shanghai Hile Bio-Technology had annual revenue of 271.04M with 12.59% growth.
Revenue (ttm)
246.35M
Revenue Growth
+11.70%
P/S Ratio
12.81
Revenue / Employee
673.10K
Employees
366
Market Cap
3.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 271.04M | 30.32M | 12.59% |
| Dec 31, 2023 | 240.72M | -59.27M | -19.76% |
| Dec 31, 2022 | 299.99M | -47.30M | -13.62% |
| Dec 31, 2021 | 347.29M | 88.16M | 34.02% |
| Dec 31, 2020 | 259.13M | -18.86M | -6.79% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cabio Biotech (Wuhan) | 574.88M |
| Suzhou Fushilai Pharmaceutical | 439.57M |
| Guangdong VTR Bio-Tech | 830.87M |
| Landfar Bio-medicine | 125.47M |
| Novoprotein Scientific | 151.51M |
| Shanghai Model Organisms Center | 421.26M |
| Jiangsu Sihuan Bioengineering | 341.90M |
| Beijing Kawin Technology Share-Holding | 1.15B |